Breaking News

Maryland's COVID-19 Vaccine Confirms High Levels of Efficacy Against Variants

March 11, 2021 • 6:13 pm CST
(Precision Vaccinations News)

Maryland-based Novavax, Inc. announced the final efficacy of 96.4% against mild, moderate, and severe disease caused by the original COVID-19 strain in a pivotal Phase 3 trial in the United Kingdom of NVX‑CoV2373, the company’s vaccine candidate.

Novavax also announced the complete analysis of its Phase 2b trial in South Africa, with an efficacy of 55.4% among the HIV- negative trial participants in a region where the vast majority of strains are B1.351 escape variants.

Across both studies, the NVX-CoV2373 vaccine demonstrated 100% protection against severe COVID-19 disease, including all hospitalization and death.

“We are very encouraged by the data showing that NVX-CoV2373 not only provided complete protection against the most severe forms of the disease but also dramatically reduced mild and moderate disease across both trials,” said Stanley C. Erck, President, and Chief Executive Officer, Novavax.

"Importantly, both studies confirmed efficacy against the variant strains. “

"Today marks one year since the WHO officially declared the COVID-19 pandemic, and with this data in hand, we are even more motivated to advance our vaccine as a potential weapon in the fight to end the suffering caused by COVID-19, concluded Erck's comments in a related press statement.

Today’s final analyses build on the successful interim results announced in January 2021, adding substantially more COVID-19 cases and statistical power. Both studies achieved their statistical success criteria, stated the company.

Novavax, Inc. (Nasdaq: NVAX) is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.

Our Trust Standards: Medical Advisory Committee

Share